Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data 

Date

22 Sep 2020

Session

F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

Presenters

Enrique Grande

Authors

E. Grande

Author affiliations

  • Medical Oncology Department, MD Anderson Cancer Center Madrid, 28033 - Madrid/ES
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings